Nyxoah SA Aktie News

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robert Taub / BMI Estate On No...

Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference

Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical...

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6.504....

Nyxoah SA ( NYXH ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Pearson Dennis Olivier Taelman - CEO & Executive Director John Landry - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Adam Maeder - Piper Sandler & Co., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Jonathan Block...

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah's Chairman and Management, and a convertible bond. Mont-Saint-Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels...

REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue.

Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. ...